ViiV Healthcare announces data from Phase IIIb VOLITION study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Study Findings: The phase IIIb VOLITION study revealed that 89% of treatment-naive individuals with HIV opted to switch from daily Dovato to long-acting injectable CAB+RPV LA after achieving rapid viral suppression, highlighting the effectiveness and patient preference for the new treatment option.
Real-World Effectiveness: Multiple observational studies, including BEYOND and CARLOS, demonstrated high rates of virologic suppression and improved treatment satisfaction among patients using CAB+RPV LA, reinforcing its efficacy and addressing challenges associated with daily oral medication.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 55.990
Low
20.15
Averages
38.72
High
55.60
Current: 55.990
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. General medicines include inhaled medicines for asthma and COPD with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. It is in phase IIb clinical development for prophylactic protection against food allergens.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
UK and US Reach Drug Tariff Exemption Agreement
- Drug Tariff Agreement: The UK government has reached an agreement with the US that UK-made drugs will be tariff-free for the next three years, significantly boosting UK pharmaceutical exports, which exceed £5 billion annually.
- Cost-Effectiveness Standard Increase: The deal mandates the UK's National Institute for Health and Care Excellence (NICE) to raise its cost-effectiveness threshold by 25%, which will encourage pharmaceutical companies to adjust drug pricing competitively, impacting market supply.
- New Drug Price Increase: The National Health Service (NHS) will pay 25% higher list prices for new prescription drugs, potentially increasing the financial burden on patients while also affecting pharmaceutical companies' profit structures.
- Increased R&D Investment: The UK will raise its drug R&D spending from 0.3% to 0.6% of GDP, a strategic investment aimed at enhancing the UK's competitiveness in the global pharmaceutical industry and fostering innovation and long-term growth.
See More
GSK and Shionogi Complete ViiV Healthcare Transaction
- Transaction Completion: GSK and Shionogi have finalized the transaction for ViiV Healthcare, with Shionogi increasing its economic interest from 11.7% to 21.7%, while GSK retains a majority stake of 78.3%, ensuring its dominant position in the joint venture.
- Financial Flow: In this transaction, Shionogi acquired newly issued shares of ViiV for $2.125 billion, while Pfizer's stake was canceled, resulting in Pfizer receiving $1.875 billion in cash, indicating ongoing market confidence in ViiV's prospects.
- Special Dividend: GSK received a special dividend of $250 million from the transaction, which not only enhances its cash flow but also provides funding for future investments, further solidifying its position in the pharmaceutical industry.
- Stock Performance: At the last close, GSK shares were trading at 2,064.00 pence, up 0.05%, reflecting a positive market reaction to the transaction, which may boost investor confidence in GSK's future growth potential.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Stock Futures Edge Higher Amid Geopolitical Tensions and Energy Market Pressures
- Bitdeer Partnership: Bitdeer Technologies (BTDR) shares rose 3% after announcing a partnership with DCI to develop its Tydal facility in Norway into an AI data center, expected to deliver 180 MW of capacity by December 2026, enhancing its competitive position in the AI sector.
- GSK Drug Approval: GlaxoSmithKline (GSK) shares gained 2% following the approval of Exdensur by China's NMPA as an add-on treatment for severe eosinophilic asthma in patients aged 12 and older, based on Phase 3 SWIFT trials showing significant reduction in exacerbation rates, likely boosting market share.
- Rocket Lab Launch Success: Rocket Lab USA (RKLB) shares advanced 2% after completing its 85th launch, successfully deploying two satellites for the European Space Agency's Celeste navigation demonstration mission, underscoring its commitment to supporting global government space programs.
- Origin Materials Revenue Drop: Origin Materials (ORGN) shares plunged 17% after reporting weak Q4 results, with revenue falling to $3.0M from $9.2M a year ago, driven by a planned reduction in its supply chain activation program, leading to a net loss of $194.1M, reflecting significant operational challenges.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
UK and US Reach Drug Tariff Exemption Agreement
- Drug Tariff Agreement: The UK government has reached an agreement with the US that UK-made drugs will be tariff-free for the next three years, significantly boosting UK pharmaceutical exports, which exceed £5 billion annually.
- Cost-Effectiveness Standard Increase: The deal mandates the UK's National Institute for Health and Care Excellence (NICE) to raise its cost-effectiveness threshold by 25%, which will encourage pharmaceutical companies to adjust drug pricing competitively, impacting market supply.
- New Drug Price Increase: The National Health Service (NHS) will pay 25% higher list prices for new prescription drugs, potentially increasing the financial burden on patients while also affecting pharmaceutical companies' profit structures.
- Increased R&D Investment: The UK will raise its drug R&D spending from 0.3% to 0.6% of GDP, a strategic investment aimed at enhancing the UK's competitiveness in the global pharmaceutical industry and fostering innovation and long-term growth.
See More
GSK and Shionogi Complete ViiV Healthcare Transaction
- Transaction Completion: GSK and Shionogi have finalized the transaction for ViiV Healthcare, with Shionogi increasing its economic interest from 11.7% to 21.7%, while GSK retains a majority stake of 78.3%, ensuring its dominant position in the joint venture.
- Financial Flow: In this transaction, Shionogi acquired newly issued shares of ViiV for $2.125 billion, while Pfizer's stake was canceled, resulting in Pfizer receiving $1.875 billion in cash, indicating ongoing market confidence in ViiV's prospects.
- Special Dividend: GSK received a special dividend of $250 million from the transaction, which not only enhances its cash flow but also provides funding for future investments, further solidifying its position in the pharmaceutical industry.
- Stock Performance: At the last close, GSK shares were trading at 2,064.00 pence, up 0.05%, reflecting a positive market reaction to the transaction, which may boost investor confidence in GSK's future growth potential.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Stock Futures Edge Higher Amid Geopolitical Tensions and Energy Market Pressures
- Bitdeer Partnership: Bitdeer Technologies (BTDR) shares rose 3% after announcing a partnership with DCI to develop its Tydal facility in Norway into an AI data center, expected to deliver 180 MW of capacity by December 2026, enhancing its competitive position in the AI sector.
- GSK Drug Approval: GlaxoSmithKline (GSK) shares gained 2% following the approval of Exdensur by China's NMPA as an add-on treatment for severe eosinophilic asthma in patients aged 12 and older, based on Phase 3 SWIFT trials showing significant reduction in exacerbation rates, likely boosting market share.
- Rocket Lab Launch Success: Rocket Lab USA (RKLB) shares advanced 2% after completing its 85th launch, successfully deploying two satellites for the European Space Agency's Celeste navigation demonstration mission, underscoring its commitment to supporting global government space programs.
- Origin Materials Revenue Drop: Origin Materials (ORGN) shares plunged 17% after reporting weak Q4 results, with revenue falling to $3.0M from $9.2M a year ago, driven by a planned reduction in its supply chain activation program, leading to a net loss of $194.1M, reflecting significant operational challenges.
See More
